Table 2. Effects of E2, fulvestrant and gefitinib on cell cycle progression in KPL-3C and MDA-MB-231 cells.

Cell line	Treatment	G0/G1	S	G2/M	Sub-G1
KPL-3C	Control	69.0±0.1a	15.5±0.5	12.7±0.7	2.9±0.1
	E2	57.7±0.3**	21.6±0.4**	18.4±0.4**	2.3±0.3
	E2+FULb	62.9±0.1**	17.1±0.1*	15.2±0.2**	4.8±0.2**
	E2+GEFc	68.1±0.1	13.9±0.1*	14.7±0.3**	3.2±0.2
	E2+FUL+GEF	80.2±0.2**	7.9±0.1**	8.2±0.2**	3.7±0.3
	GEF	79.5±1.5**	7.1±0.8**	7.2±0.2**	5.7±0.2**
MDA-MB-231	Control	58.8±0.8	16.7±0.3	14.7±0.3	9.8±0.2
	GEF	49.3±0.7*	16.5±0.5	12.6±0.4*	21.6±0.6**

^aPercentages (mean±s.e.).

^bFulvestrant.

^cGefitinib.

^*P<0.05;

^**P<0.01 in comparison with the respective control.